Facebook Instagram X-twitter Linkedin

Ara-290 (10mg)

Table of Contents

  • Quickstart Highlights

Ara-290 (10mg) protocols focus on this synthetic peptide derived from the helix B region of erythropoietin (EPO), designed to activate the innate repair receptor (CD131) without stimulating erythropoiesis. It is researched for its potential anti-inflammatory, tissue-protective, and neuroprotective effects, particularly in metabolic, neuropathic, and inflammatory conditions.

This guide outlines an educational subcutaneous administration framework for the 10 mg vial format.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration
  • Typical range: 1–4 mg per dose (subcutaneous or research-use protocols)
  • Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the research protocol.

  • Goal: Support tissue repair, reduce inflammation, and promote cellular protection via CD131 receptor activation
  • Schedule: Typically administered daily or several times per week, depending on protocol design
  • Dose Range: 1–4 mg per administration
  • Cycle Use: Often used in cycles depending on research goals (e.g., 2–4 weeks or longer structured protocols)
  • Dosing Protocol

Suggested approach for the 10 mg vial format.

  • Start: 1 mg per dose to assess tolerance
  • Target: 2–4 mg per dose based on protocol goals
  • Frequency: 1–3 times per week or daily in structured cycles
  • Vial Duration: One 10 mg vial typically lasts 2–10 doses, depending on protocol intensity
  • Timing: Flexible; often used consistently at the same time each day or session
  • Mechanism of Action

Ara-290 (also known as Cibinetide) is an 11-amino acid synthetic peptide derived from erythropoietin but engineered to remove hematopoietic activity while preserving tissue-protective signaling.

It selectively activates the innate repair receptor complex (EPOR/CD131), which triggers downstream anti-inflammatory and cytoprotective pathways. This signaling is associated with reduced inflammatory cytokine activity, improved cellular survival, and enhanced tissue repair mechanisms.

Preclinical and early clinical research suggest potential benefits in neuropathic pain, metabolic dysfunction, and inflammatory disorders through modulation of immune response and mitochondrial protection.

  • Potential Benefits & Side Effects

Observations based on preclinical and early-stage clinical research.

Potential Benefits:

  • May reduce inflammation and support immune regulation
  • May promote nerve repair and reduce neuropathic pain signals
  • May support tissue protection and cellular recovery pathways
  • Investigated for metabolic and chronic inflammatory conditions

Possible Side Effects:

  • Mild injection-site irritation
  • Occasional headache or fatigue was reported in some studies
  • Generally well tolerated in research settings
  • Long-term safety in broader populations is not fully established; it remains investigational